Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor, Inc. reports developments as a life science tools company supplying mission-critical products and services to life sciences and advanced technology customers through its VWR Distribution & Services and Bioscience & Medtech Products businesses. Recurring updates cover earnings, cash flow, leverage, guidance, segment performance and the company’s Revival transformation program, including VWR brand activity, manufacturing and supply-chain improvements and e-commerce upgrades.
Company news also covers portfolio and infrastructure actions such as Masterflex fluid handling systems, single-use assemblies, peristaltic pumps, J.T. Baker high-purity process chemicals, and expanded microbial and stability testing capabilities for regulated biopharma manufacturing. Governance and management updates include finance leadership changes and appointments tied to bioscience, medtech products and enterprise transformation.
Avantor (NYSE: AVTR) announced a chairman transition: independent director Gregory L. Summe will become Chairman of the Board effective January 1, 2026. Current Chairman Jonathan Peacock will step down as chairman and as a director at the end of 2025 after nearly nine years of service.
Since joining the board in 2020, Mr. Summe has chaired the Nominating and Governance Committee and served on the Compensation Committee. The company referenced its recent CEO change to Emmanuel Ligner and the addition of Greg Lucier to the board as part of its current governance composition.
Avantor (NYSE: AVTR) announced on October 3, 2025 that Gregory T. Lucier has been appointed to its Board of Directors. Mr. Lucier brings more than three decades of life sciences leadership, currently serving as Executive Chairman and CEO of Corza Medical, Chairman of the Board at Dentsply Sirona, and a board member of Maravai LifeSciences. He previously served as Chairman and CEO of NuVasive and Life Technologies. The board and chairman Jonathan Peacock said Lucier’s experience will support Avantor’s focus on driving growth and profitability across its Lab Solutions and Bioscience Production segments and delivering sustainable shareholder value.
Avantor (NYSE:AVTR), a global provider of mission-critical products and services for life sciences and advanced technology industries, will release its Q3 2025 financial results before market open on Wednesday, October 29, 2025.
The company will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the results. Investors can access the live audio webcast through the Events & Presentations section of Avantor's investor relations website at ir.avantorsciences.com. A replay will be available for 30 days following the presentation.
Avantor (NYSE:AVTR), a global provider of life sciences and advanced technology products, has responded to Engine Capital's letter by reaffirming its commitment to shareholder value creation. The company highlighted several strategic initiatives, including the appointment of Emmanuel Ligner as CEO effective August 18, 2025, the implementation of a $400 million cost transformation program, and successful debt reduction of $1.5 billion over the past 18 months.
The Board emphasized its focus on strengthening growth and profitability in Laboratory Solutions and Bioscience Production segments, while highlighting recent leadership changes and increased business transparency through resegmentation efforts.
Engine Capital LP, owning approximately 3% of Avantor (NYSE:AVTR), has sent a letter to the company's Board of Directors highlighting opportunities to enhance shareholder value. The activist investor criticizes Avantor's underperformance, citing ineffective cost controls and poor capital deployment that have led to significant value destruction.
Engine Capital sees potential for 100% share price appreciation by the end of 2027 through implementing cost discipline, operational improvements, portfolio optimization, and immediate share repurchases. The investor also emphasizes the need for board refreshment with directors experienced in healthcare distribution, capital allocation, and relevant leadership roles.
Avantor (NYSE:AVTR) reported mixed Q2 2025 financial results with net sales of $1.68 billion, showing a 1% decrease year-over-year, while organic revenue remained flat. The company posted net income of $64.7 million, down from $92.9 million in Q2 2024, with diluted EPS of $0.09 and adjusted EPS of $0.24.
The Laboratory Solutions segment saw a 3% decline in net sales to $1.12 billion, while Bioscience Production grew 3% to $561.3 million. The company generated operating cash flow of $154.4 million and free cash flow of $125.4 million, maintaining an adjusted net leverage of 3.2x.
Additionally, Avantor announced a significant leadership change, with Emmanuel Ligner appointed as the new President and CEO, effective August 18, 2025, replacing Michael Stubblefield.
Avantor (NYSE:AVTR) has appointed Emmanuel Ligner as its new President and Chief Executive Officer, effective August 18, 2025. Ligner, who brings over 30 years of life sciences industry experience, will succeed Michael Stubblefield.
Ligner's extensive background includes 12 years at GE Life Sciences in global leadership positions, serving as President and CEO of Cytiva where he integrated Pall Life Sciences, and most recently as CEO of Cerba HealthCare. The appointment aims to drive competitive growth in both Lab Solutions and Bioscience Production divisions.
Avantor (NYSE:AVTR), a leading provider of mission-critical products and services for life sciences and advanced technology industries, has scheduled its Q2 2025 earnings release and conference call. The financial results will be released before market open on Friday, August 1, 2025, followed by a conference call at 8:00 a.m. Eastern Time. Investors can access the live audio webcast through the Events & Presentations section of Avantor's investor relations website, with a replay available for 30 days.
Avantor (NYSE: AVTR), a leading provider of mission-critical products and services for life sciences and advanced technology industries, announced that its Executive Vice President and CFO Brent Jones will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference. The event will take place on May 20, 2025 at approximately 8:00 a.m. Eastern Time in New York.
Investors can access the presentation slides and live audio webcast through the Events & Presentations section of Avantor's investor relations website. The presentation materials will remain available on the website, and a replay of the webcast will be accessible for 30 days following the event.
Avantor (NYSE: AVTR), a leading provider of mission-critical products and services for life sciences and advanced technology industries, has announced its participation in the Bank of America Securities 2025 Health Care Conference. The company's President and CEO, Michael Stubblefield, will engage in a fireside chat at the event in Las Vegas on May 13, 2025, at 10:00 a.m. Pacific Time. Investors can access a live audio webcast through Avantor's investor relations website, with a replay available for 30 days following the presentation.